A new drug called Letairis (ambrisentan) plus new guidelines are updating treatment for pulmonary arterial hypertension
August 2007
Please see the August 2012 FDA warning concerning the use of Revatio in children with PAH
In pulmonary arterial hypertension, there is continuous high blood pressure in the pulmonary arteries...which carry oxygen-poor blood from the right ventricle to the lungs.
It's a rare condition that's due to tightening of pulmonary arteries...thickening of the walls of pulmonary arteries...or to blockages caused by blood clots in smaller arteries.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote